Page 12 - Small Molecules News Today

Lonza Group AG (OTCMKTS:LZAGY – Get Rating) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 2,300 shares, a decline of 74.2% from the February 28th total of 8,900 shares. Based on an average daily trading volume, of 133,000 shares, the short-interest ratio […]

Data Bridge Market Research analyses that the pharmaceutical logistics market which is USD 227.45 billion in 2022, is expected to reach USD 446.61 billion...

Lonza Group AG / Key word(s): AGMEGM27-March-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Annual General Meeting to take place on 5 May 2023 at the Congress Center in Basel...

Lonza Group AG / Key word(s): AGMEGM Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports 27-March-2023 / 07:00 CET/CEST Release of an ad hoc announcement

Shares of Lonza Group AG (OTCMKTS:LZAGY – Get Rating) have been assigned a consensus rating of “Buy” from the eight analysts that are covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have updated their coverage on the stock in […]

/PRNewswire/ -- The "Global Pharmaceutical Continuous Manufacturing Market, Growth Opportunities" report has been added to ResearchAndMarkets.coms offering....

Lonza Group AG / Key word(s): Expansion Lonza Completes Expansion of Conjugation Facility in Visp (CH) 16.02.2023 / 14:00 CET/CEST Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates The Visp (CH) in...

In a recent study published in the Proceedings of the National Academy of Sciences, researchers assessed the capability of two small molecules of disintegrating alpha-synuclein fibrils.

The infamous spike proteins on the surface of SARS-CoV-2 help it bind to and enter human cells. Because of their important role in spreading infection, these spike proteins are one of the main targets for COVID-19 vaccines and treatments.

Lonza Group AG / Key word(s): Bond/Financing Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon 08.02.2023 / 18:3...